{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:16:40Z","timestamp":1769973400411,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007423","name":"Duchenne Parent Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017732","name":"E-Rare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.nmd.2025.105275","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:05:47Z","timestamp":1737072347000},"page":"105275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double\u2013blind, placebo\u2013controlled, phase 3 trial (TAMDMD Group B)"],"prefix":"10.1016","volume":"47","author":[{"given":"Bettina C.","family":"Henzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3920-8058","authenticated-orcid":false,"given":"Niveditha","family":"Putananickal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rubino\u2013Nacht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schaedelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Amthor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2013Marie","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Horrocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Houwen\u2013van Opstal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Laugel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes Lopez","family":"Lobato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s Nascimento","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schara\u2013Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Spinty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpad","family":"von Moers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier M.","family":"Dorchies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-9201","authenticated-orcid":false,"given":"Dirk","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.105275_bib0001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0002","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","article-title":"The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review","volume":"16","author":"Szabo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2025.105275_bib0003","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","article-title":"Emerging therapies for Duchenne muscular dystrophy","volume":"21","author":"Markati","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0004","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2025.105275_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nmd.2025.105275_bib0006","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/WCO.0b013e328364fbaf","article-title":"Pharmacological prospects in the treatment of Duchenne muscular dystrophy","volume":"26","author":"Ruegg","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.647010","article-title":"Abnormal calcium handling in duchenne muscular dystrophy: mechanisms and potential therapies","volume":"12","author":"Mareedu","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.nmd.2025.105275_bib0008","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.biocel.2010.11.005","article-title":"Duchenne muscular dystrophy\u2013what causes the increased membrane permeability in skeletal muscle?","volume":"43","author":"Allen","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.nmd.2025.105275_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/GCO.0000000000000424","article-title":"Hormone receptor positive breast cancer: state of the art","volume":"30","author":"Peddi","year":"2018","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.nmd.2025.105275_bib0010","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/0006-2952(94)90073-6","article-title":"Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity","volume":"47","author":"Custodio","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nmd.2025.105275_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/taap.1998.8510","article-title":"Tamoxifen inhibits induction of the mitochondrial permeability transition by Ca2+ and inorganic phosphate","volume":"152","author":"Custodio","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.nmd.2025.105275_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0960-0760(91)90292-D","article-title":"Tamoxifen and oestrogen both protect the rat muscle against physiological damage","volume":"40","author":"Koot","year":"1991","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.nmd.2025.105275_bib0013","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/jsre.2001.6350","article-title":"Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia","volume":"103","author":"Kuhn","year":"2002","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.nmd.2025.105275_bib0014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.sap.0000199155.73000.2f","article-title":"Down-regulating causes of fibrosis with tamoxifen: a possible cellular\/molecular approach to treat rhinophyma","volume":"56","author":"Payne","year":"2006","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.nmd.2025.105275_bib0015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjp.0706265","article-title":"Modulation of mitochondrial Ca(2+) uptake by estrogen receptor agonists and antagonists","volume":"145","author":"Lobaton","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nmd.2025.105275_bib0016","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","article-title":"The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy","volume":"182","author":"Dorchies","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2025.105275_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jama.2021.9941","article-title":"Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement","volume":"326","author":"Orkin","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.nmd.2025.105275_bib0018","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.nmd.2025.105275_bib0019","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S1474-4422(23)00285-5","article-title":"Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Henzi","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/dmcn.13590","article-title":"Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials","volume":"60","author":"Schreiber","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1469-8749.2009.03316.x","article-title":"Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor function measure","volume":"52","author":"Vuillerot","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0022","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00004703-199006000-00004","article-title":"Assessing psychosocial adjustment of children with chronic illnesses: a review of the technical properties of PARS III","volume":"11","author":"Walker","year":"1990","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.nmd.2025.105275_bib0023","doi-asserted-by":"crossref","first-page":"g1340","DOI":"10.1136\/bmj.g1340","article-title":"Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis","volume":"348","author":"Geersing","year":"2014","journal-title":"Bmj"},{"key":"10.1016\/j.nmd.2025.105275_bib0024","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nmd.2025.105275_bib0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.nmd.2021.05.005","article-title":"Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy","volume":"31","author":"Tsabari","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.105275_bib0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1469-8749.2012.04345.x","article-title":"A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy","volume":"54","author":"Mazzone","year":"2012","journal-title":"Dev Med Child Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:26:31Z","timestamp":1741695991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S0960896625000021"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105275","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double\u2013blind, placebo\u2013controlled, phase 3 trial (TAMDMD Group B)","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105275"}}